Tier 1 — highest

Quercetin Actions on Lipid Profiles in Overweight and Obese Individuals: A Systematic Review and Meta-Analysis

Wenfang Guo, Xue Gong, Minhui Li
Current pharmaceutical design 2019 25(28):3087-3095

Bibliography

PubMed
PMID 31465275
DOI
10.2174/1381612825666190829153552
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignSystematic review and meta-analysis of randomized trials
ModelHuman evidence synthesis
Sample9 trials in adults with overweight or obesity
InterventionQuercetin across trial-specific doses
DurationSearches through March 20, 2019
EndpointsLipid measurements

What the study showed, in plain terms

Published in 2019, this source examined cardiovascular and metabolic health. Its evidence base was 9 trials in adults with overweight or obesity. It evaluated Quercetin across trial-specific doses across Searches through March 20, 2019.

Overall LDL, HDL, triglycerides, and total cholesterol did not differ significantly; selected higher-dose subgroups favored LDL reduction.

Small heterogeneous trial set and subgroup analyses. The main result does not support a reliable general lipid-lowering effect.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Overall LDL, HDL, triglycerides, and total cholesterol did not differ significantly; selected higher-dose subgroups favored LDL reduction.
  • The recorded outcome domains were Lipid measurements.
  • This synthesis reuses the included study populations; it is not an additional randomized participant cohort.

What this study can and cannot tell us

  • Small heterogeneous trial set and subgroup analyses. The main result does not support a reliable general lipid-lowering effect.
  • Pooled estimates depend on the included trials and may share participants with companion publications or other reviews. A statistically significant surrogate outcome does not establish disease prevention.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022
Tier 1
The effects of quercetin supplementation on lipid profiles and inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials
Reza Tabrizi et al. · Critical reviews in food science and nutrition · 2020

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology